Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit

Rhea-AI Summary

Cullinan Therapeutics (Nasdaq: CGEM) will participate in a fireside chat at the Citi 2026 Virtual Oncology Leadership Summit on Thursday, February 19, 2026 at 10:00 a.m. ET. Speakers include CEO Nadim Ahmed and CMO Jeffrey Jones, M.D., M.B.A.

A live webcast will be available under the Events and Presentations section of the company’s investor relations website: https://investors.cullinantherapeutics.com/events.

Key Figures

Summit date: February 19, 2026 Event time: 10:00 a.m. ET Price change: 5.18% +5 more

8 metrics

Summit date February 19, 2026 Date of Citi 2026 Virtual Oncology Leadership Summit fireside chat

Event time 10:00 a.m. ET Scheduled time of the Citi summit fireside chat

Price change 5.18% CGEM 24-hour price change prior to this news

52-week range $5.68 – $13.43 CGEM 52-week low and high before this news

Market cap $684,693,842 CGEM market capitalization prior to this announcement

200-day MA $8.69 CGEM 200-day moving average before this news

Relative volume 0.73x Today’s volume vs 20-day average ahead of this news

Short interest 13.77% Reported short interest as share of float

Market Reality Check

Price: $12.19 Vol: Volume 493,770 is below 2...

normal vol

$12.19 Last Close

Volume Volume 493,770 is below 20-day average 677,917 (relative volume 0.73x). normal

Technical Price 12.19 is trading above 200-day MA at 8.69, indicating a pre-existing uptrend.

Peers on Argus

CGEM was up 5.18% with mixed peers: AUTL up 7.09%, INBX up 5.03%, while PRTC dow...

1 Down

CGEM was up 5.18% with mixed peers: AUTL up 7.09%, INBX up 5.03%, while PRTC down 1.08% and others flat. Momentum scanner only flagged FULC moving down, supporting a stock-specific move rather than a coordinated sector rotation.

Historical Context

5 past events · Latest: Feb 05 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 05	Conference appearance	Neutral	-3.9%	Management fireside chat at Guggenheim Emerging Outlook: Biotech Summit 2026.
Jan 08	Corporate update	Positive	+1.8%	2026 pipeline milestones and cash runway update highlighting <b>$439.0M</b> liquidity.
Dec 08	Clinical data update	Positive	+17.5%	Updated Phase 1 CLN-049 AML data with meaningful response rates and durability.
Dec 01	Regulatory designation	Positive	-5.5%	FDA Fast Track designation for CLN-049 in relapsed/refractory AML.
Nov 20	Regulatory filing	Positive	+3.2%	Initiation of rolling NDA submission for zipalertinib in EGFR ex20ins NSCLC.

Pattern Detected

Positive clinical and regulatory updates have often seen aligned positive moves, while some regulatory wins showed near-term negative reactions.

Recent Company History

Over the past few months, Cullinan reported several major milestones. A Nov 20, 2025 NDA rolling submission for zipalertinib and a Dec 1, 2025 FDA Fast Track designation for CLN-049 underscored regulatory progress. Updated CLN-049 data on Dec 8, 2025 drove a strong positive move. A Jan 8, 2026 corporate update highlighted 2026 clinical catalysts and a $439.0 million cash position, followed by conference participation news on Feb 5, 2026. Today’s conference appearance continues this investor-relations cadence.

Market Pulse Summary

This announcement highlights Cullinan Therapeutics’ participation in a Citi-hosted oncology leadersh...

Analysis

This announcement highlights Cullinan Therapeutics’ participation in a Citi-hosted oncology leadership summit, continuing a pattern of active investor-relations engagement. Recent history includes substantial clinical and regulatory milestones, plus a strong cash position of $439.0 million and expected runway into 2029. Investors may monitor upcoming clinical readouts, regulatory decisions for zipalertinib, and further updates on CLN-049 and CLN-978 as more material value drivers than conference appearances.

AI-generated analysis. Not financial advice.

CAMBRIDGE, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Citi 2026 Virtual Oncology Leadership Summit on Thursday, February 19, 2026, at 10:00 a.m. ET.

A webcast of the fireside chat will be available under the Events and Presentations section of the Company’s investor relations website at https://investors.cullinantherapeutics.com/events.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, high-impact therapies for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow Cullinan on LinkedIn and X.

Contacts:

Investors
Nick Smith
+1 401.241.3516
nsmith@cullinantx.com

Media
Rose Weldon
+1 215.801.7644
rweldon@cullinantx.com

FAQ

When will Cullinan Therapeutics (CGEM) present at the Citi 2026 Virtual Oncology Leadership Summit?

Cullinan will present on February 19, 2026 at 10:00 a.m. ET. According to the company, CEO Nadim Ahmed and CMO Jeffrey Jones will participate in a fireside chat discussing the company’s clinical-stage programs and strategy.

Who from Cullinan Therapeutics (CGEM) will speak at the Citi 2026 Virtual Oncology Leadership Summit?

The company named CEO Nadim Ahmed and CMO Jeffrey Jones, M.D., M.B.A. as participants. According to the company, they will join a fireside chat to discuss clinical progress and the company’s oncology agenda with summit attendees.

How can investors watch Cullinan Therapeutics (CGEM) at the Citi 2026 summit?

A webcast will be available via the company’s investor relations site under Events and Presentations. According to the company, the fireside chat webcast will be posted at https://investors.cullinantherapeutics.com/events for on-demand viewing.

What topics will Cullinan Therapeutics (CGEM) cover in the February 19, 2026 fireside chat?

The fireside chat will focus on the company’s clinical-stage programs and oncology strategy. According to the company, CEO and CMO will discuss program updates, scientific rationale, and clinical development priorities for autoimmune and cancer therapeutics.

Is the Cullinan Therapeutics (CGEM) fireside chat at Citi 2026 available after the live event?

Yes, the webcast will be available for later viewing on the investor relations site. According to the company, the recorded fireside chat will be posted under Events and Presentations for investors to access post-event.